Vanessa Bianconi1, Amirhossein Sahebkar2, Stephen L Atkin3, Matteo Pirro1. 1. Unit of Internal Medicine, Department of Medicine, University of Perugia, Hospital 'Santa Maria della Misericordia', Perugia, Italy. 2. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Weill Cornell Medicine Qatar, Doha, Qatar.
Abstract
PURPOSE OF REVIEW: Monocyte chemoattractant protein (MCP)-1, a chemokine regulating monocyte chemotaxis and T-lymphocyte differentiation by binding to the CC chemokine receptor 2 (CCR2), plays a crucial role in the pathogenesis of inflammatory diseases, atherosclerosis and cancer. This review summarizes the current knowledge on the regulation and importance of the MCP-1/CCR2 axis, focusing on the therapeutic potential of its inhibition. RECENT FINDINGS: Differential modulation of MCP-1 and CCR2 lead to downstream activation pathways, pathogenetic to differing disease conditions characterized by dysregulated monocyte/macrophage tissue recruitment. Pharmacological targeting of the MCP-1/CCR2 axis has led to selective MCP-1/CCR2 antagonists that have now entered phase I/II clinical trials for the treatment of inflammatory diseases, atherosclerosis and cancer. The pleiotropic nonselective MCP-1/CCR2 inhibition by current pharmacological agents is thought to contribute to their anti-inflammatory and antiatherosclerotic effects that is also seen for nutraceutical compounds such as curcumin. SUMMARY: MCP-1 has a critical role in regulating chemotaxis both in health and disease, with increasing interest in its pharmacological inhibition. However, the therapeutic efficacy and safety of targeting the MCP-1/CCR2 axis is still in evolution.
PURPOSE OF REVIEW: Monocyte chemoattractant protein (MCP)-1, a chemokine regulating monocyte chemotaxis and T-lymphocyte differentiation by binding to the CC chemokine receptor 2 (CCR2), plays a crucial role in the pathogenesis of inflammatory diseases, atherosclerosis and cancer. This review summarizes the current knowledge on the regulation and importance of the MCP-1/CCR2 axis, focusing on the therapeutic potential of its inhibition. RECENT FINDINGS: Differential modulation of MCP-1 and CCR2 lead to downstream activation pathways, pathogenetic to differing disease conditions characterized by dysregulated monocyte/macrophage tissue recruitment. Pharmacological targeting of the MCP-1/CCR2 axis has led to selective MCP-1/CCR2 antagonists that have now entered phase I/II clinical trials for the treatment of inflammatory diseases, atherosclerosis and cancer. The pleiotropic nonselective MCP-1/CCR2 inhibition by current pharmacological agents is thought to contribute to their anti-inflammatory and antiatherosclerotic effects that is also seen for nutraceutical compounds such as curcumin. SUMMARY:MCP-1 has a critical role in regulating chemotaxis both in health and disease, with increasing interest in its pharmacological inhibition. However, the therapeutic efficacy and safety of targeting the MCP-1/CCR2 axis is still in evolution.
Authors: Laurel A Grisanti; Claudio de Lucia; Toby P Thomas; Aron Stark; John T Strony; Valerie D Myers; Remus Beretta; Daohai Yu; Celestino Sardu; Raffaele Marfella; Erhe Gao; Steven R Houser; Walter J Koch; Eman A Hamad; Douglas G Tilley Journal: JCI Insight Date: 2019-03-28
Authors: Christine A Schneider; Dario X Figueroa Velez; Ricardo Azevedo; Evelyn M Hoover; Cuong J Tran; Chelsie Lo; Omid Vadpey; Sunil P Gandhi; Melissa B Lodoen Journal: Proc Natl Acad Sci U S A Date: 2019-11-14 Impact factor: 11.205
Authors: Ewa Migacz; Wioletta Olejarz; Alicja Głuszko; Katarzyna Bednarek-Rajewska; Robert Proczka; David F Smith; Stacey L Ishman; Wojciech Kukwa Journal: Diagnostics (Basel) Date: 2021-05-22